ImmuSmol
Private Company
Total funding raised: $1.2M
Overview
ImmuSmol is a specialized reagent and assay provider focusing on the challenging niche of small-molecule immunodetection. Leveraging over a decade of expertise in anti-hapten antibody development, the company offers a validated portfolio of ELISA kits and antibodies for key analytes in neuroscience, immunometabolism, and endocrinology research. Its business model is built on direct sales and a distributor network, catering primarily to the academic and biopharmaceutical research markets. The company appears to be in a revenue-generating, commercial stage with a focused product-driven strategy.
Technology Platform
Proprietary platform for generating and validating high-specificity anti-hapten antibodies against small molecules, enabling development of ELISA kits and antibodies for immuno-staining (IHC/IF/ICC).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Operates in a specialized niche with limited direct competitors focused solely on small-molecule immunoassays. Faces indirect competition from larger reagent suppliers (e.g., Thermo Fisher, Abcam) and alternative technology platforms like LC-MS/MS offered by core facilities or service providers. Differentiation is achieved through deep expertise, high-specificity validation, and a pathway-focused product portfolio.